{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:53:43Z","timestamp":1761490423449,"version":"build-2065373602"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.medmal.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T03:30:15Z","timestamp":1511321415000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents"],"prefix":"10.1016","volume":"48","author":[{"given":"H.G.","family":"Maxwell-Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.D.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2017.10.008_bib0435","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhin.2015.12.004","article-title":"Faceal microbiota transplantation for recurrent Clostridium difficile infection and beyond: risks and regulation","volume":"92","author":"Goldenberg","year":"2016","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.medmal.2017.10.008_bib0440","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0445","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.10.008_bib0450","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with clostridium difficile in Europe Canada, and the United State of America: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0455","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0460","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/ice.2014.88","article-title":"Risk factors for recurrent clostridium difficile infection: a systematic review and meta-analysis","volume":"36","author":"Deshpande","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0465","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15010-013-0496-x","article-title":"Treatment of recurrent Clostridium difficile infection: a systematic review","volume":"42","author":"O\u2019Horo","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.medmal.2017.10.008_bib0470","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","article-title":"Recurrent Clostridium difficile infection is associated with increased mortality","volume":"21","author":"Olsen","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2017.10.008_bib0475","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12864","article-title":"Clinical predictors of recurrent Clostridium difficile infection in out-patients","volume":"40","author":"Shivashankar","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medmal.2017.10.008_bib0480","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ajg.2016.187","article-title":"Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: The RECIDIVISM study","volume":"111","author":"Razik","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0485","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJMe1013236","article-title":"The search for effective treatment of clostridium difficile infection","volume":"364","author":"Dupont","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.10.008_bib0490","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0495","doi-asserted-by":"crossref","first-page":"e53757","DOI":"10.1371\/journal.pone.0053757","article-title":"Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate","volume":"8","author":"Lynch","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medmal.2017.10.008_bib0500","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0505","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjmed.2014.05.016","article-title":"Effect of treatment variation on outcomes in patients with Clostridium difficile","volume":"127","author":"Brown","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.medmal.2017.10.008_bib0510","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10096-015-2538-z","article-title":"The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations","volume":"35","author":"Goldenberg","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0515","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/imj.13027","article-title":"Australasian society of infectious diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand","volume":"46","author":"Trubiano","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.medmal.2017.10.008_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20Suppl. 2","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2017.10.008_bib0525","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0530","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0535","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/506349","article-title":"Tolevamer, a novel nonanibiotic polymer, compared with vancomycin in the treatment of mild to moderately sever Clostridium difficile-associated diarrhea","volume":"43","author":"Louie","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0540","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.medmal.2017.10.008_bib0545","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/cis440","article-title":"Reduced acquisition and overgrowth of vancomycin-resistant enterococci and candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"55","author":"Nerandzic","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0550","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.medmal.2017.10.008_bib0555","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.medmal.2017.10.008_bib0560","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiol"},{"issue":"2","key":"10.1016\/j.medmal.2017.10.008_bib0565","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0570","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C Difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0575","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite (OP-1118) against C.\u00a0difficile","volume":"55","author":"Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0580","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"55","author":"Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2017.10.008_bib0585","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0590","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1128\/AAC.01611-12","article-title":"Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores","volume":"57","author":"Allen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0595","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dks450","article-title":"Fidaxomicin inhibits toxin production in Clostridium difficile","volume":"68","author":"Babakhani","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0600","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12941-016-0140-6","article-title":"A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin","volume":"15","author":"Thabit","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.medmal.2017.10.008_bib0605","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0610","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1310\/hpj4905-420","article-title":"Vigabatrin-Induced encephalopathy; fidaxomicin hypersensitivity reactions; vemurafenib-induced DRESS; severe alkalosis and hypokalemia with stanozolol misuse; isotretinoin-associated lip abscess; eltrombopag-associated hyperpigmentation","volume":"49","author":"Mancano","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.medmal.2017.10.008_bib0615","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/infdis\/jit598","article-title":"Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile","volume":"209","author":"Eyre","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.medmal.2017.10.008_bib0620","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0625","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.medmal.2017.10.008_bib0630","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.medmal.2017.10.008_bib0635","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","article-title":"Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin","volume":"31","author":"Cornely","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.medmal.2017.10.008_bib0640","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/phar.1479","article-title":"The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer","volume":"34","author":"Esmaily-Fard","year":"2014","journal-title":"Pharmacother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0645","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection (EXTEND): a randomised, controlled, open-label study in an older patient population","author":"Guery","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0650","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/phar.1451","article-title":"An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series","volume":"34","author":"Vargo","year":"2014","journal-title":"Pharmacother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0655","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/AAC.00939-15","article-title":"Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection","volume":"59","author":"Gallagher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0660","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dku261","article-title":"Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison","volume":"69","author":"Cornely","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0665","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1128\/AAC.04268-14","article-title":"Fidaxomicin therapy in critically ill patients with Clostridium difficile infection","volume":"59","author":"Penziner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0670","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10096-016-2802-x","article-title":"The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort","volume":"36","author":"Feh\u00e9r","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0675","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhin.2015.01.015","article-title":"Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin","volume":"90","author":"Biswas","year":"2015","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.medmal.2017.10.008_bib0680","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","article-title":"Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial","volume":"117","author":"Johnson","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medmal.2017.10.008_bib0685","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0690","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.10.008_bib0695","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2015.11.537","article-title":"Outcomes of deflect-1: a multicenter, blinded, randomized clinical trial of fidaxomicin (FDX) vs. placebo (PLC) for prophylaxis of Clostridium difficile associated diarrhea (CDAD) in subjects undergoing hematopoietic stem cell transplantation (HSCT)","volume":"22","author":"Mullane","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2017.10.008_bib0700","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jac\/dkv498","article-title":"Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C.\u00a0Difficile infection","volume":"71","author":"Bass\u00e8res","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0705","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.02184-13","article-title":"Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal clostridium species: implications for Clostridium difficile recurrence","volume":"58","author":"Goldstein","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0710","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkv006","article-title":"In vitro susceptibility of clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C.\u00a0difficile","volume":"70","author":"Corbett","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0715","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12879-015-0759-5","article-title":"A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections","volume":"15","author":"Vickers","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0720","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0725","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1473-3099(17)30237-2","article-title":"Expanding the armamentarium for the treatment of Clostridium difficile infection","volume":"17","author":"Goldenberg","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0730","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01831-13","article-title":"Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0735","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.01830-13","article-title":"In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0740","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkt411","article-title":"In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C.\u00a0difficile infection","volume":"69","author":"Chilton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0745","doi-asserted-by":"crossref","first-page":"e00384","DOI":"10.1128\/AAC.00384-17","article-title":"Different resistance mechanisms for cadazolid and linezolid in C.\u00a0difficile found by whole genome sequencing analysis","volume":"61","author":"Caspers","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0750","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ijantimicag.2015.07.015","article-title":"Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection","volume":"46","author":"Gehin","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2017.10.008_bib0755","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1128\/AAC.00504-15","article-title":"A multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic, cadazolid, in patients with Clostridium difficile infection","volume":"59","author":"Louie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0775","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1128\/AAC.00057-12","article-title":"In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile","volume":"56","author":"Mascio","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0780","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/jac\/dkw246","article-title":"Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial","volume":"71","author":"Lee","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0785","first-page":"4: ofw275","article-title":"Primary outcomes from a phase 3, randomised, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection","author":"Boix","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medmal.2017.10.008_bib0790","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1128\/AAC.06354-11","article-title":"Mechanism of action of, and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571","volume":"56","author":"Leeds","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0795","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1128\/AAC.06305-11","article-title":"Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria","volume":"56","author":"Citron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0800","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1128\/AAC.06355-11","article-title":"Efficacy of LFF571 in a hamster model of Clostridium difficile infection","volume":"56","author":"Trzasko","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0805","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.04436-14","article-title":"Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile","volume":"59","author":"Sachdeva","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0810","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1128\/AAC.00867-12","article-title":"A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers","volume":"56","author":"Ting","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0815","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/AAC.04252-14","article-title":"Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections","volume":"59","author":"Bhansali","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0820","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/AAC.04251-14","article-title":"Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections","volume":"59","author":"Mullane","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0825","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jac\/dkp037","article-title":"Comparative in vitro activity of REP3123 against clostridium difficile and other anaerobic intestinal bacteria","volume":"63","author":"Citron","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0830","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jac\/dkp042","article-title":"Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model","volume":"63","author":"Ochsner","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0835","doi-asserted-by":"crossref","first-page":"e02761","DOI":"10.1128\/AAC.02760-16","article-title":"Safety, tolerability, systemic exposure and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile infections, in a phase I study","volume":"61","author":"Nayak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0840","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.anaerobe.2014.07.001","article-title":"In vitro activity of MCB3681 against Clostridium difficile strains","volume":"28","author":"Rashid","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.medmal.2017.10.008_bib0845","doi-asserted-by":"crossref","first-page":"e02077","DOI":"10.1128\/AAC.02077-16","article-title":"In vitro activities of MCB3681 and eight comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread","volume":"61","author":"Freeman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.10.008_bib0850","doi-asserted-by":"crossref","first-page":"767.e1","DOI":"10.1016\/j.cmi.2015.05.025","article-title":"Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle","volume":"21","author":"Dalhoff","year":"2015","journal-title":"Clin Microbiol Infect"},{"year":"2016","series-title":"A single-centre, double-blind, placebo-controlled study in healthy men to assess the safety and tolerability of single and repeated ascending doses of MGB-BP-3, a new class of antibacterial agent","author":"Ravic","key":"10.1016\/j.medmal.2017.10.008_bib0860"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17308673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17308673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:15:54Z","timestamp":1759972554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X17308673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0399077X17308673"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2017.10.008","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}